Traditionally, chronic kidney disease (CKD) has been regarded as a progressive, irreversible condition, with treatment goals limited to slowing its progression to end-stage renal disease. However, the emergence of a series of novel therapies in recent years has fundamentally changed this pessimistic narrative. Sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, […]